• / Free eNewsletters & Magazine
  • / My Account
Home>Ipsen: 2015 Half-Year Results

Ipsen: 2015 Half-Year Results

3party Content

Fri, 31 Jul 2015

Ipsen: 2015 Half-Year Results Group sales up 7.9%1 driven by solid 12.0%1 growth of Specialty care, notably due to Somatuline® Core Operating Income up 3.5%, in view of the investment in neuroendocrine tumors Fully diluted core EPS up 7.0% 2015 objectives raised Regulatory News: The Board of
Upcoming Events

©2014 Morningstar Advisor. All right reserved.